Managing R&D Progress Against Milestones
First written in FY2019. 1 of 2 entries say "Restated". Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023RestatedAnnual report
「We are pursuing a broad range of R&D activities, from basic research on regenerative medical products for cancer immunotherapy and treatment of intractable diseases, through technology development aimed at commercialization, to clinical application, and are managing and operating these activities to achieve progress in line with milestones.」
The Company has continued its policy of advancing research and development from basic research through clinical application and managing progress in line with milestones. - FY2019First statedAnnual report
「We are pursuing a broad range of R&D activities, from basic research on regenerative medical products for cancer immunotherapy and treatment of intractable diseases, through technology development aimed at commercialization, to clinical application, and are managing and operating these activities to achieve progress in line with milestones.」
The Company manages R&D from basic research through clinical application in line with milestones.